How might the ability of GLP-1 receptor agonists to promote satiety and delay gastric emptying influence both short-term and long-term management strategies for obesity and Type 2 diabetes
On March 10 th , the FDA issued guidance clarifying that 503A and 503B drug compounders must soon cease compounding semaglutide injection products[i] or risk enforcement action.[ii] This has a significant impact on compounding pharmacies as, under the Federal Food, Drug, and Cosmetic Act (the FD&C ), drug compounders are permitted to compound their own copies of a patented drug if the FDA determines it is in shortage
White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes
Repeated injections in the same spot can cause lipohypertrophy, firm lumps that may alter absorption, so comfort today should not come at the cost of using one favorite spot every week
He notes that upgraded reta will turbocharge fat burning by targeting GLP-1 and other key hormones, and then the myostatin inhibitor will turbocharge our ability to build muscle
